866-997-4948(US-Canada Toll Free)

Anaplastic Astrocytoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 41 Pages


Global Markets Directs, \'Anaplastic Astrocytoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma. 

Anaplastic Astrocytoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Anaplastic Astrocytoma.
  • A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Anaplastic Astrocytoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaplastic Astrocytoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Anaplastic Astrocytoma 7
Anaplastic Astrocytoma Therapeutics under Development by Companies 9
Anaplastic Astrocytoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Anaplastic Astrocytoma Therapeutics - Products under Development by Companies 14
Anaplastic Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Anaplastic Astrocytoma Therapeutics Development 16
Amgen Inc. 16
Pfizer Inc. 17
Peregrine Pharmaceuticals, Inc. 18
EirGen Pharma Ltd. 19
Anaplastic Astrocytoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
leflunomide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
survivin peptide vaccine + [montanide ISA-51] + [sargramostim] - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
nintedanib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bevacizumab + [carboplatin] - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AMG-595 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
carmustine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Eir-060 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Anaplastic Astrocytoma Therapeutics - Discontinued Products 36
Anaplastic Astrocytoma Therapeutics - Dormant Products 37
Anaplastic Astrocytoma - Product Development Milestones 38
Featured News & Press Releases 38
Feb 29, 2012: Antisense Pharma Terminates Phase III High Grade Glioma Trial And Expands First-Line Treatment With Trabedersen 38
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 38
Jan 08, 2007: Hana Biosciences Announces 2007 Corporate Goals 39
Jun 09, 2006: Hana Biosciences Receives Orphan Drug Designation For Ropidoxuridine (IPdR), For The Treatment Of Malignant Glioma 39

Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Table


Number of Products Under Development for Anaplastic Astrocytoma, H1 2013 7
Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Amgen Inc., H1 2013 16
Pfizer Inc., H1 2013 17
Peregrine Pharmaceuticals, Inc., H1 2013 18
EirGen Pharma Ltd., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Anaplastic Astrocytoma Therapeutics - Discontinued Products 36
Anaplastic Astrocytoma Therapeutics - Dormant Products 37

List of Chart


Number of Products under Development for Anaplastic Astrocytoma, H1 2013 7
Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Combination Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *